We are live on
!
Find out more
MCM
M28 Capital Management Portfolio holdings
AUM
$53.8M
1-Year Est. Return
28.63%
This Fund
S&P 500
This Quarter
Est. Return
-37.21%
1 Year Est. Return
+28.63%
3 Year Est. Return
+218.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$19.3M
(-15%)
Cap. Flow
+$34.7M
Cap. Flow
% of AUM
31.94%
Top 10 Holdings %
Top 10 Hldgs %
95.32%
Holding
14
New
2
Increased
7
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$6.51M |
| 2 |
TG Therapeutics
TGTX
|
+$6.03M |
| 3 |
Curis
CRIS
|
+$5.22M |
| 4 |
Wave Life Sciences
WVE
|
+$5.11M |
| 5 |
VERV
Verve Therapeutics
VERV
|
+$5.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$7.57M |
| 2 |
Atara Biotherapeutics
ATRA
|
+$860K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.71% |
| 2 | Financials | 4.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Invivyd
IVVD
$218M
| $29.2M | 26.83% |
6,398,250
+733,029
| +13% | +$4.48M |
|
|
2
Wave Life Sciences
WVE
$1.2B
| $11.7M | 10.76% |
5,850,000
+2,084,412
| +55% | +$5.11M |
|
3
Rocket Pharmaceuticals
RCKT
$394M
| $11.4M | 10.44% |
715,880
+220,600
| +45% | +$3.81M |
|
4
Stoke Therapeutics
STOK
$2.11B
| $11.1M | 10.2% |
527,150
| – | – |
|
|
5
Curis
CRIS
$7.83M
| $10.1M | 9.29% |
10,608
+4,086
| +63% | +$5.22M |
|
|
6
TG Therapeutics
TGTX
$7.62B
| $9.97M | 9.16% |
1,047,900
+520,900
| +99% | +$6.03M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.82M | 6.27% |
82,900
+63,700
| +332% | +$6.51M |
|
8
BridgeBio Pharma
BBIO
$16.5B
| $4.73M | 4.35% |
466,200
| – | – |
|
|
CYPH
9
Cypherpunk Technologies Inc
CYPH
$73.3M
| $4.66M | 4.29% |
266,440
+166,440
| +166% | +$3.56M |
|
|
VERV
10
DELISTED
Verve Therapeutics
VERV
| $4.07M | 3.74% |
+178,500
| New | +$5.1M |
|
|
11
Atara Biotherapeutics
ATRA
$76.1M
| $3.62M | 3.33% |
15,574
-2,701
| -15% | -$860K |
|
12
ProQR Therapeutics
PRQR
$265M
| $907K | 0.83% |
+1,001,800
| New | +$3.36M |
|
|
NEXI
13
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $562K | 0.52% |
5,338
| – | – |
|
|
14
Nektar Therapeutics
NKTR
$2.58B
| – | – |
-37,373
| Closed | -$7.57M |
|
Similar funds
NCM
WEO
CAM
ETCM
AA
TP
GMEI
FRGX
M28 Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, M28 Capital Management held 14 positions worth $109M, down 15% from $128M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
M28 Capital Management deployed $34.7M of net new capital in Q1 2022, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was Verve Therapeutics: 178,500 shares worth $4.07M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Atara Biotherapeutics, an estimated $860K trimmed.
- M28 Capital Management's largest Q1 2022 buy was Verve Therapeutics: 178,500 shares worth $4.07M.
- M28 Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q1 2022, an estimated $6.51M increase.
- M28 Capital Management's biggest Q1 2022 reduction was Atara Biotherapeutics, cutting an estimated $860K.
- M28 Capital Management fully exited Nektar Therapeutics in Q1 2022, selling an estimated $7.57M.
- M28 Capital Management's ten largest holdings make up 95% of its $109M portfolio in Q1 2022.
- M28 Capital Management opened 2 new positions and closed 1 in Q1 2022.
- M28 Capital Management's portfolio value fell 15% quarter-over-quarter to $109M.
Based on M28 Capital Management's 13F filing for Q1 2022, filed 13 May 2022.